MwanzoPRQR • NASDAQ
add
ProQR Therapeutics NV
Bei iliyotangulia
$ 2.40
Bei za siku
$ 2.35 - $ 2.54
Bei za mwaka
$ 1.61 - $ 4.62
Thamani ya kampuni katika soko
254.17M USD
Wastani wa hisa zilizouzwa
elfu 342.38
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 3.98M | 190.58% |
Matumizi ya uendeshaji wa biashara | 12.70M | 44.93% |
Mapato halisi | -8.11M | -42.00% |
Kiwango cha faida halisi | -203.67 | 51.13% |
Mapato kwa kila hisa | -0.08 | 0.41% |
EBITDA | -8.03M | -18.95% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 89.40M | -25.84% |
Jumla ya mali | 106.85M | -24.77% |
Jumla ya dhima | 81.87M | -14.45% |
Jumla ya hisa | 24.98M | — |
hisa zilizosalia | 81.68M | — |
Uwiano wa bei na thamani | 7.74 | — |
Faida inayotokana na mali | -19.38% | — |
Faida inayotokana mtaji | -46.15% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -8.11M | -42.00% |
Pesa kutokana na shughuli | -5.66M | 24.65% |
Pesa kutokana na uwekezaji | 16.71M | 5,030.38% |
Pesa kutokana na ufadhili | elfu -453.00 | -61.21% |
Mabadiliko halisi ya pesa taslimu | 10.43M | 230.22% |
Mtiririko huru wa pesa | elfu 743.50 | 156.44% |
Kuhusu
ProQR Therapeutics NV is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2012
Tovuti
Wafanyakazi
157
